Nura Bio raised $73.8 million in a Series B to advance two early clinical programs targeting SARM1, a pathway implicated in axon degeneration. The funding is intended to support progression through early human studies and additional development activities across the company’s pipeline. By focusing on SARM1 inhibition, Nura Bio is aligning with broader neurodegeneration drug development efforts that aim to preserve neural integrity rather than only treat symptoms. The financing underscores continued investor appetite for mechanism-driven neuroscience assets as companies work to translate target biology into repeatable clinical efficacy.